Relay drug shows early promise against rare blood vessel diseases
Summary:
In a mid-stage clinical trial, Relay Therapeutics’ drug candidate zovegalisib demonstrated a 60% response rate in patients with rare vascular anomalies, offering potentially superior safety and efficacy compared to Novartis’ existing treatment, Vijoice.
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
Summary:
The FDA approved Daiichi Sankyo and AstraZeneca’s Datroway for first-line triple-negative breast cancer, pulling ahead of rival Gilead by demonstrating a five-month survival advantage over chemotherapy.
AI can design viruses, toxins and other bioweapons. How worried should we be?
Summary:
While emerging biological AI tools could theoretically be misused to design undetectable toxins or enhanced pathogens, a recent NASEM report highlights significant technical bottlenecks in lab production and data limitations, suggesting that current biosecurity risks remain manageable.
Mutating Antibodies for Easier Drug-Conjugate Manufacturing
Summary:
Johns Hopkins University scientists created a general-purpose antibody with six mutations in its Fc region, offering a customizable system to ease manufacturing and improve consistency of antibody-drug conjugates.
